Abstract
Objective: We aimed to investigate the safety and efficacy of HL301, a standardized combination product of seven medicinal plants, in radiation pneumonitis in patients with unresectable non-small cell lung cancer (NSCLC) undergoing curative concurrent chemoradiotherapy.Methods: The target accrual was 87 and a total of 63 patients were enrolled due to poor accrual rate. We randomly assigned the 63 patients to receive a placebo (arm A), or 1200 mg HL301 (arm B), or 1800 mg HL301 (arm C). Patients received weekly paclitaxel and carboplatin concurrently with intensity-modulated radiotherapy at 60–66 Gy in conventional fractionation. Durvalumab was administered as maintenance treatment according to standard clinical practice. HL301 was administered orally, daily for 12 weeks. The primary endpoint was incidence of grade ≥2 radiation pneumonitis at 24 weeks post-chemoradiotherapy.Results: The baseline characteristics of the patients were well balanced. The drug was tolerable with a compliance rate of 86.6%, 86.2%, and 88.8% in arms A, B, and C, respectively (P = 0.874). None of the patients experienced severe drug-related adverse events. No significant difference in the rate of adverse events were observed between the treatment arms. The incidence of grade ≥2 radiation pneumonitis at 24 weeks post-chemoradiotherapy was 37.5% (95% CI, 18.5–61.4%), 55.6% (95% CI, 33.7–75.4%), and 52.4% (95% CI, 32.4–71.7%) in arms A, B, and C, respectively (P=0.535).Conclusion: This is the first exploratory clinical trial to test the safety and efficacy of HL301 in patients with NSCLC. Safety and feasibility of HL301 were established but no signals of efficacy in reducing RP was observed in this dose level.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.